PIK3CA and breast carcinoma: Moreover, Kallergi and collaborators [68] were able to assess the activation of the PI3K-AKT-mTOR pathway in two groups of patients with early (n = 16) and metastatic (n = 16) breast cancer, reporting high expression levels of phospho-PI3K and phospho-AKT in CTCs from both populations.